Monogram Orthopedics issues 3D-printed FDA-approved implants unique to each patient’s anatomy.
“By 2027 50 [percent] of knee replacement surgeries will be performed robotically. Monogram is currently the only company offering FDA-approved, 3D-printed, patient-specific implants that, in the future, will be inserted with active milling robots,” Benjamin Sexson, Monogram’s CEO, said in a May 9 press release.
By listing its securities on the stock exchange, Monogram will be beholden to disclosure, filing and notification requirements, as well as compliance with applicable continued quantitative and qualitative listing standards.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
